Pharmacological consequences of EGFR targeting;Conséquences pharmacologiques du ciblage du récepteur du facteur de croissance épidermique

Bulletin du Cancer

Volumn 90, Issue SPEC. ISS., 2003, Pages

  Milano, Gérard ^a   Magné, Nicolas ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Anticancer drugs; Chemosensitization; EGF receptor; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; IRINOTECAN; TAXANE DERIVATIVE;

APOPTOSIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; DNA REPAIR; DRUG TARGETING; HUMAN; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0346874159     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
2. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-74.
3. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 m Ab 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18: 731-8.
4. Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14: 451-63.
5. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998; 17: 999-1007.
6. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000; 82: 1991-9.
7. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Bitocchio A, Zupi G, et al. ZD1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in BCl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002; 98: 463-9.
8. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001; 291: 1284-9.
9. Jeggo PA. DNA-PK: at the cross-roads of biochemistry and genetics. Mutation Research 1997; 384: 1-14.
10. Bandyopadhyay D, Mandal M, Adamn L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273: 1568-73.
11. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874-84.
12. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-92.
13. Overholset JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancrearic carcinoma xenograft in nude mice. Cancer 2000; 89: 74-82.
14. Magné N, Fischel JL, Dubreuil A, Formento P, Marcié S, Lagrange JL, Milano G. Sequence-dependent effects of ZD1839 (Iressa) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86: 819-27.
15. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19: 419-27.
16. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-33.
17. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4367-42.
18. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, et al Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909-16.
19. Prewett MC, Hooper At, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003.
20. Chou T, Talalay P. Quantitative analysis of dose-effects relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
21. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-95.
22. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13: 65-72.
23. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, et al. The characterization of novel, dual ErbB2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61: 7196-203.
24. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the ErbB family of receptor tyrosine kinases. Sem Oncol 2001; 28: 67-79.
25. Osborne CK, Schiff R, Fuqua SAW, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7: S4338-42.
26. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869-72.
27. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. J Biol Chem 2001; 276: 9817-24.
28. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001; 7: S4436-42.
29. Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 2001; 12: 841-6.
30. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-101.
31. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62: 200-7.